Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats

Cristina Zalfa, Laura Rota Nodari, Elena Vacchi, Maurizio Gelati, Daniela Profico, Marina Boido, Elena Binda, Lidia De Filippis, Massimiliano Copetti, Valentina Garlatti, Paola Daniele, Jessica Rosati, Alessandro De Luca, Francesca Pinos, Laura Cajola, Alberto Visioli, Letizia Mazzini, Alessandro Vercelli, Maria Svelto, Angelo Luigi VescoviDaniela Ferrari

Research output: Contribution to journalArticle

Abstract

Stem cells are emerging as a therapeutic option for incurable diseases, such as Amyotrophic Lateral Sclerosis (ALS). However, critical issues are related to their origin as well as to the need to deepen our knowledge of the therapeutic actions exerted by these cells. Here, we investigate the therapeutic potential of clinical-grade human neural stem cells (hNSCs) that have been successfully used in a recently concluded phase I clinical trial for ALS patients (NCT01640067). The hNSCs were transplanted bilaterally into the anterior horns of the lumbar spinal cord (four grafts each, segments L3–L4) of superoxide dismutase 1 G93A transgenic rats (SOD1 rats) at the symptomatic stage. Controls included untreated SOD1 rats (CTRL) and those treated with HBSS (HBSS). Motor symptoms and histological hallmarks of the disease were evaluated at three progressive time points: 15 and 40 days after transplant (DAT), and end stage. Animals were treated by transient immunosuppression (for 15 days, starting at time of transplantation). Under these conditions, hNSCs integrated extensively within the cord, differentiated into neural phenotypes and migrated rostro-caudally, up to 3.77 ± 0.63 cm from the injection site. The transplanted cells delayed decreases in body weight and deterioration of motor performance in the SOD1 rats. At 40DAT, the anterior horns at L3–L4 revealed a higher density of motoneurons and fewer activated astroglial and microglial cells. Accordingly, the overall survival of transplanted rats was significantly enhanced with no rejection of hNSCs observed. We demonstrated that the beneficial effects observed after stem cell transplantation arises from multiple events that counteract several aspects of the disease, a crucial feature for multifactorial diseases, such as ALS. The combination of therapeutic approaches that target different pathogenic mechanisms of the disorder, including pharmacology, molecular therapy and cell transplantation, will increase the chances of a clinically successful therapy for ALS.

Original languageEnglish
Article number345
JournalCell Death and Disease
Volume10
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Transgenic Rats
Neural Stem Cells
Disease Progression
Transplantation
Amyotrophic Lateral Sclerosis
Survival
Horns
Therapeutics
Transplants
Clinical Trials, Phase I
Cell Transplantation
Stem Cell Transplantation
Motor Neurons
Immunosuppression
Superoxide Dismutase-1
Spinal Cord
Stem Cells
Body Weight
Pharmacology
Phenotype

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats. / Zalfa, Cristina; Rota Nodari, Laura; Vacchi, Elena; Gelati, Maurizio; Profico, Daniela; Boido, Marina; Binda, Elena; De Filippis, Lidia; Copetti, Massimiliano; Garlatti, Valentina; Daniele, Paola; Rosati, Jessica; De Luca, Alessandro; Pinos, Francesca; Cajola, Laura; Visioli, Alberto; Mazzini, Letizia; Vercelli, Alessandro; Svelto, Maria; Vescovi, Angelo Luigi; Ferrari, Daniela.

In: Cell Death and Disease, Vol. 10, No. 5, 345, 01.05.2019.

Research output: Contribution to journalArticle

Zalfa, Cristina ; Rota Nodari, Laura ; Vacchi, Elena ; Gelati, Maurizio ; Profico, Daniela ; Boido, Marina ; Binda, Elena ; De Filippis, Lidia ; Copetti, Massimiliano ; Garlatti, Valentina ; Daniele, Paola ; Rosati, Jessica ; De Luca, Alessandro ; Pinos, Francesca ; Cajola, Laura ; Visioli, Alberto ; Mazzini, Letizia ; Vercelli, Alessandro ; Svelto, Maria ; Vescovi, Angelo Luigi ; Ferrari, Daniela. / Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats. In: Cell Death and Disease. 2019 ; Vol. 10, No. 5.
@article{a4cc64e33c2648aab4c3f3d354c4ce33,
title = "Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats",
abstract = "Stem cells are emerging as a therapeutic option for incurable diseases, such as Amyotrophic Lateral Sclerosis (ALS). However, critical issues are related to their origin as well as to the need to deepen our knowledge of the therapeutic actions exerted by these cells. Here, we investigate the therapeutic potential of clinical-grade human neural stem cells (hNSCs) that have been successfully used in a recently concluded phase I clinical trial for ALS patients (NCT01640067). The hNSCs were transplanted bilaterally into the anterior horns of the lumbar spinal cord (four grafts each, segments L3–L4) of superoxide dismutase 1 G93A transgenic rats (SOD1 rats) at the symptomatic stage. Controls included untreated SOD1 rats (CTRL) and those treated with HBSS (HBSS). Motor symptoms and histological hallmarks of the disease were evaluated at three progressive time points: 15 and 40 days after transplant (DAT), and end stage. Animals were treated by transient immunosuppression (for 15 days, starting at time of transplantation). Under these conditions, hNSCs integrated extensively within the cord, differentiated into neural phenotypes and migrated rostro-caudally, up to 3.77 ± 0.63 cm from the injection site. The transplanted cells delayed decreases in body weight and deterioration of motor performance in the SOD1 rats. At 40DAT, the anterior horns at L3–L4 revealed a higher density of motoneurons and fewer activated astroglial and microglial cells. Accordingly, the overall survival of transplanted rats was significantly enhanced with no rejection of hNSCs observed. We demonstrated that the beneficial effects observed after stem cell transplantation arises from multiple events that counteract several aspects of the disease, a crucial feature for multifactorial diseases, such as ALS. The combination of therapeutic approaches that target different pathogenic mechanisms of the disorder, including pharmacology, molecular therapy and cell transplantation, will increase the chances of a clinically successful therapy for ALS.",
author = "Cristina Zalfa and {Rota Nodari}, Laura and Elena Vacchi and Maurizio Gelati and Daniela Profico and Marina Boido and Elena Binda and {De Filippis}, Lidia and Massimiliano Copetti and Valentina Garlatti and Paola Daniele and Jessica Rosati and {De Luca}, Alessandro and Francesca Pinos and Laura Cajola and Alberto Visioli and Letizia Mazzini and Alessandro Vercelli and Maria Svelto and Vescovi, {Angelo Luigi} and Daniela Ferrari",
year = "2019",
month = "5",
day = "1",
doi = "10.1038/s41419-019-1582-5",
language = "English",
volume = "10",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats

AU - Zalfa, Cristina

AU - Rota Nodari, Laura

AU - Vacchi, Elena

AU - Gelati, Maurizio

AU - Profico, Daniela

AU - Boido, Marina

AU - Binda, Elena

AU - De Filippis, Lidia

AU - Copetti, Massimiliano

AU - Garlatti, Valentina

AU - Daniele, Paola

AU - Rosati, Jessica

AU - De Luca, Alessandro

AU - Pinos, Francesca

AU - Cajola, Laura

AU - Visioli, Alberto

AU - Mazzini, Letizia

AU - Vercelli, Alessandro

AU - Svelto, Maria

AU - Vescovi, Angelo Luigi

AU - Ferrari, Daniela

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Stem cells are emerging as a therapeutic option for incurable diseases, such as Amyotrophic Lateral Sclerosis (ALS). However, critical issues are related to their origin as well as to the need to deepen our knowledge of the therapeutic actions exerted by these cells. Here, we investigate the therapeutic potential of clinical-grade human neural stem cells (hNSCs) that have been successfully used in a recently concluded phase I clinical trial for ALS patients (NCT01640067). The hNSCs were transplanted bilaterally into the anterior horns of the lumbar spinal cord (four grafts each, segments L3–L4) of superoxide dismutase 1 G93A transgenic rats (SOD1 rats) at the symptomatic stage. Controls included untreated SOD1 rats (CTRL) and those treated with HBSS (HBSS). Motor symptoms and histological hallmarks of the disease were evaluated at three progressive time points: 15 and 40 days after transplant (DAT), and end stage. Animals were treated by transient immunosuppression (for 15 days, starting at time of transplantation). Under these conditions, hNSCs integrated extensively within the cord, differentiated into neural phenotypes and migrated rostro-caudally, up to 3.77 ± 0.63 cm from the injection site. The transplanted cells delayed decreases in body weight and deterioration of motor performance in the SOD1 rats. At 40DAT, the anterior horns at L3–L4 revealed a higher density of motoneurons and fewer activated astroglial and microglial cells. Accordingly, the overall survival of transplanted rats was significantly enhanced with no rejection of hNSCs observed. We demonstrated that the beneficial effects observed after stem cell transplantation arises from multiple events that counteract several aspects of the disease, a crucial feature for multifactorial diseases, such as ALS. The combination of therapeutic approaches that target different pathogenic mechanisms of the disorder, including pharmacology, molecular therapy and cell transplantation, will increase the chances of a clinically successful therapy for ALS.

AB - Stem cells are emerging as a therapeutic option for incurable diseases, such as Amyotrophic Lateral Sclerosis (ALS). However, critical issues are related to their origin as well as to the need to deepen our knowledge of the therapeutic actions exerted by these cells. Here, we investigate the therapeutic potential of clinical-grade human neural stem cells (hNSCs) that have been successfully used in a recently concluded phase I clinical trial for ALS patients (NCT01640067). The hNSCs were transplanted bilaterally into the anterior horns of the lumbar spinal cord (four grafts each, segments L3–L4) of superoxide dismutase 1 G93A transgenic rats (SOD1 rats) at the symptomatic stage. Controls included untreated SOD1 rats (CTRL) and those treated with HBSS (HBSS). Motor symptoms and histological hallmarks of the disease were evaluated at three progressive time points: 15 and 40 days after transplant (DAT), and end stage. Animals were treated by transient immunosuppression (for 15 days, starting at time of transplantation). Under these conditions, hNSCs integrated extensively within the cord, differentiated into neural phenotypes and migrated rostro-caudally, up to 3.77 ± 0.63 cm from the injection site. The transplanted cells delayed decreases in body weight and deterioration of motor performance in the SOD1 rats. At 40DAT, the anterior horns at L3–L4 revealed a higher density of motoneurons and fewer activated astroglial and microglial cells. Accordingly, the overall survival of transplanted rats was significantly enhanced with no rejection of hNSCs observed. We demonstrated that the beneficial effects observed after stem cell transplantation arises from multiple events that counteract several aspects of the disease, a crucial feature for multifactorial diseases, such as ALS. The combination of therapeutic approaches that target different pathogenic mechanisms of the disorder, including pharmacology, molecular therapy and cell transplantation, will increase the chances of a clinically successful therapy for ALS.

UR - http://www.scopus.com/inward/record.url?scp=85064923195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064923195&partnerID=8YFLogxK

U2 - 10.1038/s41419-019-1582-5

DO - 10.1038/s41419-019-1582-5

M3 - Article

C2 - 31024007

AN - SCOPUS:85064923195

VL - 10

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 5

M1 - 345

ER -